CEO Interview: AstraZeneca's David Brennan

David Brennan has sharpened AstraZeneca's therapeutic area focus and embraced external R&D. The next two years will determine whether the productivity drive is working--or if more radical change is needed.

Melanie Senior

AstraZeneca PLC has proved its skills in the marketplace, with its top five drugs accounting for more than 50% of...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo